Amgen terminates rocatinlimab collaboration with Kyowa Kirin, effective upon HSR clearance

AMGEN INC

Termination agreement signed Jan 30, 2026 for 2021 License and Collaboration Agreement on rocatinlimab (KHK4083/AMG 451).
Amgen discontinuing participation; Kyowa Kirin to assume all development, manufacturing, and commercialization worldwide.
Transition effective upon satisfaction of HSR Act waiting period and other regulatory conditions.
If conditions not met by April 1, 2026 (extendable to June 1, 2026 due to government shutdown), Amgen may terminate and wind down.
Amgen and Kyowa Kirin also entering a Transition Agreement to facilitate transfer of activities.

item 1.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AMGEN INC terminated License and Collaboration Agreement with Kyowa Kirin Co., Ltd. (effective 2026-01-30).

Action: termination
Agreement: collaboration
Counterparty: Kyowa Kirin Co., Ltd.
Effective: 2026-01-30

Exact text from the filing

On January 30, 2026, Amgen Inc. (the “ Company ”) entered into a Termination Agreement (the “ Termination Agreement ”) with Kyowa Kirin Co., Ltd. (“ Kyowa Kirin ”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “ License and Collaboration Agreement ”).

View on SEC.gov

283 material agreements filed in the last 30 days. Browse all material agreements →

AMGEN INC filing history →

Source: SEC EDGAR

accession 0001193125-26-030518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.